RENE DANIEL
Medical Practice in Prospectville, PA
License number
Pennsylvania MT202537
Category
Medicine
Type
Graduate Medical Trainee
Address
Address
Prospectville, PA 19002
Personal information
See more information about RENE DANIEL at radaris.comName
Address
Phone
7930 Barnes St, Philadelphia, PA 19111
323 Daniels Rd, Ambler, PA 19002
8048 Oxford St, Philadelphia, PA 19111
7930 Barnes St, Philadelphia, PA 19111
1305 Rising Sun Ave, Philadelphia, PA 19140
Professional information
Cellular Targets For Treatment Of Retroviral Infection
US Patent:
2006002, Feb 2, 2006
Filed:
Mar 30, 2005
Appl. No.:
11/093692
Inventors:
Rene Daniel - Ambler PA, US
Anna Skalka - Princeton NJ, US
Gary Kao - Wynnewood PA, US
Giuseppi Nunnari - Cantania, IT
Roger Pomerantz - Chalfont PA, US
Anna Skalka - Princeton NJ, US
Gary Kao - Wynnewood PA, US
Giuseppi Nunnari - Cantania, IT
Roger Pomerantz - Chalfont PA, US
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435006000, 435007100
Abstract:
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
Cellular Targets For Treatment Of Retroviral Infection
US Patent:
2011008, Apr 14, 2011
Filed:
Jun 14, 2010
Appl. No.:
12/815125
Inventors:
Rene Daniel - Ambler PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US
International Classification:
C12N 5/071
US Classification:
435366, 435325
Abstract:
Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.